Aptamers Market PowerPoint PPT Presentations

Aptamers is an emerging market, widely considered as a rival or substitute to antibodies in the scientific industry. It is poised to grow rapidly in various application areas, including therapeutics and diagnostics. The global aptamers market is valued at $287 million in 2013 and is expected to reach $2.1 billion by 2018. Aptamers existed in parallel with antibodies for two decades, but its market potential was not utilized, even to a fraction of antibodies. However, the achievement of Macugen has given a boost to the aptamer field. The list of promising aptamers in the clinical trials pipeline estimates that these synthetic chemical antibodies will soon surpass monoclonal antibodies in therapeutics, diagnosis, and imaging. With technological merits over antibodies, the aptamers market is poised to grow at par with antibodies in the next 10-15 years.

A newly published report by Market Statsville Group (MSG), titled Global Aptamers Market provides an exhaustive analysis of significant industry insights and historical and projected global market figures. MSG expects the global Aptamers market will showcase an impressive CAGR from 2024 to 2033.

[171 Slides Report] Aptamers Market categories the global market By Applications - Biosensors , Biomarker Discovery , Therapeutics , Diagnostics, Drug Discovery, by Technology Trends & by Geography

The global aptamers market is estimated to garner a revenue of ~USD 11 billion by the end of 2035 by growing at a CAGR of ~24% over the forecast period, i.e., 2023 – 2035.

Global aptamers market is expected to grow to $4.98 Bn by 2027 at a growth rate of 23.2% and growth analysis by The Business Research Company.

In the Healthcare Industry, marketreportslibrary.com has added geometrical data to its huge collection labelled "Aptamers Market"

Bharatbook.com announces a new report on "Aptamers Market - Technology Trend", Aptamers is an emerging market, widely considered as a rival or substitute to antibodies in the scientific industry. It is poised to grow rapidly in various application areas, including therapeutics and diagnostics.

The global aptamers market was valued at $200 million in the year 2012. At the end of 2013, the market is expected to be $287 million and is poised to reach approximately $2.1 billion by 2018, growing at a CAGR of 49.24% from 2013 to 2018.

The Global And China Aptamers Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Aptamers industry.

This report studies the global aptamers market, with forecast to 2018.

The global aptamers market was valued at $200 million in the year 2012. At the end of 2013, the market is expected to be $287 million and is poised to reach approximately $2.1 billion by 2020, growing at a CAGR of 49.24% from 2013 to 2020.

The global D-dimer testing market size was valued at US$ 1.23 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028. A paradigm shift towards the demand for next-generation point-of-care D-dimer testing is driving the global D-dimers market.The D-dimer test is used to find out if the patient is suffering from blood clotting disorder. The clotting of blood is very important, if the blood is not clotted, it may ooze out and the patient suffers from heavy blood loss.

Global Aptamers Industry 2015 Market Analysis Survey Research Growth and Forecast Report The report provides a basic overview of Aptamers industry including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered. Browse Full Report with TOC @ http://www.marketresearchstore.com/report/global-aptamers-industry-2015-market-trends-analysis-31366

The rna targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $3.97 billion in 2028 at a compound annual growth rate (CAGR) of 22.2%.

Global oligonucleotide therapy market size is expected to reach $8.75 Bn by 2028 at a rate of 11.8%, segmented as by type, antisense oligonucleotide, aptamer, other types

The study segments Oligonucleotide Synthesis industry in light of major classification such as product type, potential markets, application, and end-user.

Nucleic acid aptamers Aptamers: molecules that bind other molecules with good affinity and specificity Usually these are proteins . . . . But they can also be RNA or DNA.

Global Oligonucleotide Therapy Market size is expected at $2.1 Bn by 2027 at a growth rate of 14.2%.

The global D-dimer testing market size was valued at US$ 1.23 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028. A paradigm shift towards the demand for next-generation point-of-care D-dimer testing is driving the global D-dimers market.The D-dimer test is used to find out if the patient is suffering from blood clotting disorder. The clotting of blood is very important, if the blood is not clotted, it may ooze out and the patient suffers from heavy blood loss.

The global biofertilizer market is estimated to garner a revenue of ~USD 7 billion by the end of 2035 by growing at a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.

The report discovers the market’s total sale that is generated by a particular firm over a time period.

Based on the recent publishing from the database of TheBusinessResearchCompany " Nucleic Acid Based Gene Therapy Market Report" includes Emerging Trends, Drivers and Restraints. https://bit.ly/3baXxw7

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction)

Market and R&D Analysis of Recombinant Protein Drugs

TBRC nucleic acid based gene therapy market report includes oncology, muscular dystrophy/ muscular disorders, rare diseases https://bit.ly/3s0Lvii

The major players covered in the global oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Read More @ https://bit.ly/32i6wtd

The major players covered in the global oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc. Read More @ https://bit.ly/3ewG3xe

The global oligonucleotide therapy market is expected to grow from $0.88 billion in 2020 to $0.98 billion in 2021 at a compound annual growth rate (CAGR) of 11.4%.

Oligonucleotide Synthesis Market worth 1,918.6 Million USD by 2020

The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period.

Synthesized oligonucleotides are used for various applications in the life science and medical industry for research purposes as a probe for DNA synthesis and sequencing, probes for the detection of complementary RNA and DNA through hybridization in clinical developments and synthesis of artificial genes.

Get sample Brocure Now @ http://tinyurl.com/h2sgua6 Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage.

The Global Molecular Imaging Market is expected to reach USD 27.72 Billion by 2025, from USD 9.36 Billion in 2017 growing at a CAGR of 6.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Synthesized oligonucleotides are used for various applications in the life science and medical industry for research purposes as a probe for DNA synthesis and sequencing, probes for the detection of complementary RNA and DNA through hybridization in clinical developments and synthesis of artificial genes.

Inverted T at 3' end (3'-3') slows exonucleolytic degradation ( R-3' ... Is marketed for adult macular degeneration (wet type) From the label: Inverted ribo-T ...

Research Beam added a report on “Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook” Enquiry about report: http://www.researchbeam.com/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook-market/enquire-about-report

"Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. Enquiry about report: http://www.researchbeam.com/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook-market/enquire-about-report

IV Diagnostics, Inc. (IV Diagnostics) is a biomedical diagnostic company that concentrates on molecular diagnostic tests for circulating tumor cells and other blood borne diseases. The company develops, tests and markets diagnostic tools that monitor and measure cancer tumor cells. Its IVDxTx platform technology, allows physicians to perform real-time diagnosis of the patient’s circulating tumor cells (CTCs) without collecting blood.

The global nucleic acid therapeutics CDMO market is expected to reach $4,463.7 Million by 2030, with a CAGR of 11.09 % during the forecast period 2021-2030.

AAA

"Regado Biosciences, Inc. - Product Pipeline Review - 2014"report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

Implement routine non-invasive prenatal diagnosis and cost ... WP Leader: Ciara O'Sullivan. Tarragona, Spain. WP 5. Psychosocial Evaluation. Physicians: ...

Alternative 5' splicing. Unwanted = longer exon. Antisense shorter isoform ... B. Bias alternative splicing ratios. Target the unwanted isoform exon-intron joint. ...

Easily attached to antigen/antibody Easily measured, with high S/N Does not interfere with antibody/antigen reaction Inexpensive/economical/non-toxic The birth of ...

Applications of Immunochemical Methods in the Clinical Laboratory Roger L. Bertholf, Ph.D. Associate Professor of Pathology University of Florida College of Medicine

... Characters One drop of mercury Simple and fast process High sensitivity partly remove ic Strong resolution Application ... Metal complex reversible ...

Title: The Impact of the Human Genome Project on Clinical Diagnostics Author: Mount Sinai Hospital Last modified by: SaRa OrTeGa Created Date: 11/27/2000 1:47:21 PM

Course LMP 1506S Clinical Applications of Genomics and Proteomics Thursday, April 15, 2004, 9-11 am MSB Room 6205 Eleftherios P. Diamandis MD,Ph.D

The Art and Power of Policy. Melody Brown Burkins, Ph.D. Associate Dean ... Ipsum dolorata wind power sept rondil gen libera calep exce indo walum ger. Memo ...

Unique individual human genetic variation mandates individual treatment. Participatory: ... equity--long term endowment--faculty. consulting and facilities ...

Pre-clinical R&D needed for regulatory filings (e.g. IND or IDE) Clinical trials ... Quantitative Tissue Imaging For Clinical Diagnosis and Treatment ...

Biotech & Pharma Biomedical career opportunities in industry * * * * * * * * * * * * Overview Science at a Company vs. Academia Attributes for Success at a Company ...

Transforming Medical Care: Modernization Directorate

NIH's primary resource for enabling commercialization of innovative high impact ... Development of Molecular Pharmacodynamic Assays for Targeted Therapies ...

minor toxic load: small percentage of non relevant adventitious materials ... contaminants: adventitious pathogens from poor DNA purification (ex endotoxins) ...